Thalassaemia. Beta thalassaemia
Conditions
Interventions
Intervention 1: Patients in the intervention group received 420 milligrams of silymarin tablets, three times per day for 3 months. Intervention 2: Patients in the control group received placebo tablet
Treatment - Drugs
Placebo
Patients in the intervention group received 420 milligrams of silymarin tablets, three times per day for 3 months.
Patients in the control group received placebo tablets, three times per day for 3 months.
Sponsors
Vice chancellor for research, Mazandaran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Patients with beta thalassemia major; History of iron chelation therapy for at least 2 years; Having relatively constant average dose of iron chelation during 3 months ago; Ferritin up to 1000 µg/L Exclusion criteria: Change therapeutic regimen with iron chelation during the study (6 months)
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum malondialdehyde, carbonyl protein and total anti-oxidant of serum level. Timepoint: 1-Before the first phase 2- After the washout period (after 2 weeks of the end of the first phase) 3- After the third phase (after 26 weeks). Method of measurement: Before the first phase - After the washout period -After the third phase. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactHadi Darvishi Khezri
Mazandaran University of Medical Sciences
Outcome results
None listed